US Chem Labs

Provider Profile Name: US Chem Labs
Website: uschemlabs.com
Provider Type: Research Peptide/Chemical Vendor
FDA Warning Letter: February 7, 2024

Operating Details

• E-commerce vendor selling research chemicals
• Received an FDA warning letter on February 7, 2024, for introducing unapproved and misbranded semaglutide, tirzepatide, and thymalin products into interstate commerce
• No prescription required for purchase at the time of enforcement action
• By December 2024, the US Chem Labs website no longer listed GLP-1 products — suggesting at least partial compliance with the FDA warning letter
• No clinical hours, no patient support infrastructure, no medical director disclosed

About the Company

US Chem Labs is an online vendor that sells semaglutide, tirzepatide, and other research peptides positioned in the same grey-market category as Synthetix Inc., Prime Peptides, Swiss Chems, and Summit Research Peptides reviewed elsewhere in this series. What sets US Chem Labs apart from its peer vendors is the breadth and specificity of the human therapeutic claims on its website at the time of FDA review, and the especially serious additional violation involving the marketing of an unapproved peptide to children.

The FDA posted warning letters to US Chem Labs and Synthetix Inc. simultaneously on February 13, 2024, for introducing unapproved and misbranded semaglutide and tirzepatide products into interstate commerce. US Chem Labs offered semaglutide and tirzepatide for sale “for research purposes,” but the products were accompanied by explicit human health claims, including weight loss and reduction of the risk of stroke and heart attack.

The core regulatory issue — identical to the other research peptide vendors in this series is that the “research only” disclaimer on the product label does not neutralize human use intent if the marketing language is directed at people with medical conditions. Despite statements on product labeling marketing the products as “research chemicals only” and “not for human consumption,” the FDA determined that evidence obtained from the website establishes the products are intended to be drugs for human use.

The specific marketing language documented by the FDA was extensive. The company’s website described semaglutide as able to improve glycemic control for people with type 2 diabetes, reduce the risks for stroke and myocardial infarction, and noted it was “quickly becoming famous for weight loss.” For tirzepatide, the website discussed improved glycemic control, weight loss, delayed or prevented need for insulin, and improved quality of life. None of this language is consistent with a product being sold for laboratory or animal research purposes.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

A particularly serious additional violation — thymalin marketed to children:

US Chem Labs went further than the other vendors in this enforcement wave in one critical respect. The FDA was particularly concerned that US Chem Labs marketed its thymalin product for use in children, specifically for treatment of immunosuppression after chemotherapy in cancer patients. Thymalin is a peptide that stimulates the thymus gland and modulates immune function. It has not been reviewed by the FDA for safety or efficacy in any population.

The FDA stated that the use of untested drugs may have unpredictable and unintended consequences, particularly in vulnerable populations such as children and infants, who may be at greater risk for adverse effects due to their varying ability to absorb, metabolize, distribute, or excrete drugs or their metabolites. Marketing an unregulated compound to families of pediatric cancer patients — who are already in an exceptionally vulnerable situation — represents a categorically more serious violation than adult weight loss marketing alone.

Partial compliance following the warning letter:

By December 2024 — approximately ten months after receiving the FDA warning letter — US Chem Labs’ website no longer listed GLP-1RA products, suggesting the company removed semaglutide and tirzepatide from its catalog in response to the enforcement action. Whether other unapproved products, including thymalin, remain available, and whether the company continues to operate in any form, is not confirmed at the time of writing. Patients should treat any US Chem Labs product as an unregulated, unapproved substance, regardless of what category it falls under.

GLP-1 Offerings and Pricing

At the time of the FDA warning letter, US Chem Labs sold injectable semaglutide and tirzepatide in research chemical format, no prescription required, no clinical evaluation, no provider oversight. The website’s marketing language described these products in direct therapeutic terms for human patients, making the “research only” label a legal fig leaf rather than a functional restriction.

Pricing at research chemical vendors in this category is typically well below licensed telehealth compounded GLP-1 programs. This differential does not reflect value; it reflects the systematic absence of the clinical safety infrastructure, pharmacy quality standards, prescriber oversight, and regulatory compliance that legitimate programs provide. With GLP-1 products removed from the website by December 2024, no current pricing data is available or meaningful for prospective patients.

What reviewers say about pricing: No independent Trustpilot, consumer health review platform, or structured review pool was identified for US Chem Labs at the time of writing. Discussion of the vendor surfaces sporadically in grey-market peptide research forums. The FDA warning letter and the documented removal of GLP-1 products from the catalog are far more clinically relevant signals for patients evaluating this vendor than any pricing data or consumer review.

Reviews from Trustpilot and Google

No independent review pool was identified for US Chem Labs at the time of writing. The removal of GLP-1 products following the FDA warning letter means no ongoing consumer experience with these products can be systematically evaluated. The regulatory record — two unapproved drug violations, a pediatric marketing violation, and at least partial compliance resulting in GLP-1 product removal- is the complete picture available for this vendor.

Compounding Pharmacies Used

US Chem Labs is not a compounding pharmacy and did not operate through the 503A or 503B compounding pharmacy framework. Products were sold as research chemicals with no disclosed manufacturing source, quality testing methodology, or pharmacy licensure verifiable by consumers. The manufacturing standards, sterility requirements, and regulatory oversight applicable to licensed compounding pharmacies did not apply here. The FDA’s direct characterization of the products as unapproved new drugs makes clear that they fell entirely outside the legitimate pharmaceutical supply chain.

Note: US Chem Labs received an FDA warning letter on February 7, 2024 — one of the earliest formal enforcement actions in this review series — for selling unapproved and misbranded semaglutide, tirzepatide, and thymalin. The FDA identified two distinct categories of violation: marketing GLP-1 drugs to adult consumers seeking weight loss without a prescription, and marketing thymalin to children with cancer for immune support — the latter drawing specific FDA concern about adverse effects in pediatric patients taking unapproved, unstudied compounds. By December 2024, GLP-1 products had been removed from the website, suggesting at least partial corrective action. US Chem Labs is not a telehealth provider, has no licensed prescriber network, and does not operate through licensed compounding pharmacies. Patients seeking GLP-1 weight loss treatment should use a licensed telehealth provider with a board-certified prescriber and 503A or 503B pharmacy sourcing. US Chem Labs appears in this review series because it is listed in the weightlossinjections.com directory alongside legitimate providers.